FORM 3
 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden hours per response... 0.5

(Print or Type Responses)
1. Name and Address of Reporting Person *
  TRAVERSA SERGIO
 2. Date of Event Requiring Statement (Month/Day/Year)
01/06/2015		 3. Issuer Name and Ticker or Trading Symbol
RELMADA THERAPEUTICS, INC. [RLMD]
(Last)
(First)
(Middle)
C/O RELMADA THERAPEUTICS, INC., 546 FIFTH AVENUE, 14TH FLOOR		 4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
__X__ Director _____ 10% Owner
__X__ Officer (give title below) _____ Other (specify below)
Chief Executive Officer
 5. If Amendment, Date Original Filed(Month/Day/Year)
(Street)

NEW YORK, NY 10036		 6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
(City)
(State)
(Zip)
Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4)		 2. Amount of Securities Beneficially Owned
(Instr. 4)		 3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)		 4. Nature of Indirect Beneficial Ownership
(Instr. 5)
Common Stock 497,708
D
 

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. SEC 1473 (7-02)
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 4)		 2. Date Exercisable and Expiration Date
(Month/Day/Year)		 3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)		 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)		 6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Options   (1) 07/10/2022 Common Stock 677,962 $ 0.8 D  
Options   (2) 09/30/2023 Common Stock 665,750 $ 0.8 D  

Reporting Owners

Reporting Owner Name / Address Relationships
Director 10% Owner Officer Other
TRAVERSA SERGIO
C/O RELMADA THERAPEUTICS, INC.
546 FIFTH AVENUE, 14TH FLOOR
NEW YORK, NY 10036		   X     Chief Executive Officer  

Signatures

/s/ Sergio Traversa 01/16/2015
**Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1) The options were granted on July 10, 2012 (the "Grant Date"). The stock options vest on the Grant Date based on the following vesting schedule: 25% of the options vest upon the Grant Date and the remaining 75% of the options, vest in equal quarterly increments over the next four (4) years, so that the last set of options shall vest in July 2016.
(2) The options were granted on September 30, 2013 (the "Grant Date"). The stock options vest on the Grant Date based on the following vesting schedule: 25% of the Options shall vest the Grant Date and the remaining 75% of the Options, shall vest in equal quarterly increments over the next four (4) years, so that the last set of options shall vest in September 2017.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.